Hydrocortisone in very preterm neonates for BPD prevention: meta-analysis and effect size modifiers

To clarify if systemic hydrocortisone, in protocols allowing to start it before the 15th day of life, prevents bronchopulmonary dysplasia (BPD) or other adverse outcomes in very preterm neonates, and to identify any possible effect size modifiers.